ELAN Company Profile and Key Details

Q: Who are the executives of ELAN?

Mr. Larbi Van LierSenior Vice President of AsiaMs. Marcela A. KirbergerExecutive Vice President, Gen. Counsel & Corporation Sec.Mr. Jeffrey N. SimmonsPres, Chief Executive Officer & DirectorMr. David Alan UrbanekExecutive Vice President of Manufacturing & QualityKaty GrissomHead of Investor RelationsMr. James M. MeerSenior Vice President & Chief Accounting OfficerMr. Shawn McKeeSenior Vice President of U.S. Companion AnimalMr. Ramiro Martin CabralExecutive Vice President & Pres of Elanco InternationalMr. David S. KinardExecutive Vice President of HR, Communications & Admin.Dr. Ellen de Brabander Ph.D.Executive Vice President of Innovation, Regulatory & Bus. Devel.Mr. Rajeev ModiExecutive Vice President of U.S. Pet Health & Global Digital TransformationMr. Chris KeeleySenior Vice President & Chief Information OfficerMr. Todd S. YoungExecutive Vice President & Chief Financial OfficerMr. Jacques ZimmowitchSenior Vice President of Global QualityDr. Ramiro Martin CabralExecutive Vice President & Pres of Elanco International

NYSE : ELAN

Elanco Animal Health

$24.11

0.25+1.05%

At Close 4:00 PM

73.78

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Elanco Animal Health Incorporated (ELAN) stock declined over -3.65%, trading at $23.23 on NYSE, down from the previous close of $24.11. The stock opened at $24.22, fluctuating between $23.03 and $24.43 in the recent session.

Stock Snapshot

24.11

Prev. Close

11.55B

Market Cap

23.025

Day Low

-49.43

P/E Ratio

-0.47

EPS (TTM)

0.24

Cash Flow per Share

24.22

Open

497.17M

Number of Shares

24.425

Day High

99.22%

Free Float in %

12.63

Book Value

2.76M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	23.93	24.37	23.90	24.11	2.61M
Apr 13, 2026	23.02	23.97	22.99	23.86	5.72M
Apr 10, 2026	23.65	23.90	22.83	23.13	3.44M
Apr 09, 2026	23.44	24.16	22.61	23.46	4.5M
Apr 08, 2026	23.31	23.98	23.31	23.60	5.22M
Apr 07, 2026	22.61	22.92	22.35	22.80	3.48M
Apr 06, 2026	22.77	22.98	22.52	22.82	4.66M
Apr 02, 2026	22.55	23.38	22.10	23.08	4.25M
Apr 01, 2026	24.15	24.48	23.10	23.12	4.87M
Mar 31, 2026	23.72	24.15	23.23	23.93	5.34M
Mar 30, 2026	23.58	23.75	23.15	23.44	5.08M
Mar 27, 2026	24.65	24.77	22.74	23.13	5.43M
Mar 25, 2026	25.35	25.68	24.98	25.50	6.94M
Mar 24, 2026	24.15	25.41	24.04	24.92	7.86M
Mar 23, 2026	24.59	24.98	24.24	24.44	4.34M
Mar 20, 2026	24.78	24.93	23.76	23.98	9.32M
Mar 19, 2026	24.40	25.44	24.27	25.12	6.63M
Mar 18, 2026	24.85	25.34	24.61	24.83	13.03M
Mar 17, 2026	23.68	25.56	23.59	25.18	15.04M
Mar 16, 2026	23.28	23.58	22.85	23.40	3.82M

Contact Details

Greenfield, IN 46140

United States

https://www.elanco.com 877 352 6261

About Company

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Stock Peers

ZTS

1.03+0.86%

Zoetis Inc.$121.11 CTLT

Catalent, Inc.$63.48 TARO

0.005+0.01%

Taro Pharmaceutical Industries Ltd.$42.98 TEVA

0.62+1.99%

Teva Pharmaceutical Industries Limited$31.77 TAK

0.03+0.17%

Takeda Pharmaceutical Company Limited$17.85 RDY

-0.14-1.06%

Dr. Reddy's Laboratories Limited$13.13 PRGO

0.16+1.41%

Perrigo Company plc$11.47 HLN

-0.13-1.32%

Haleon plc$9.70 EBS

0.42+5.10%

Emergent BioSolutions Inc.$8.66 BHC

-0.04-0.70%

Bausch Health Companies Inc.$5.68

Company Overview

Elanco Animal Health Incorporated (NYSE:ELAN) closed at $23.23 USD, losing -$0.88 (-3.65%) from the previous close of $24.11. The stock is currently mid-range between its 52-week high and low $8.02 and $27.72. With a market capitalization of about $11.55 billion, Elanco Animal Health Incorporated is classified as a large-cap and shows higher-than-market volatility (beta ~1.88). Key stats such as the average daily volume over the past year has been around 5.04 million shares, volume is running light vs its 52-week average. Headquartered in Greenfield, IN, Elanco Animal Health Incorporated operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Jeffrey N. Simmons, the company employs approximately 9,000 people and listed since September 20, 2018. Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 4.48%, SMA50 9.02%, SMA200 35.83%). The stock’s 14-day RSI is 60.73 (firm momentum), while the ATR of 0.94 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.52% below its high and over 226.56% above its low. Average 10-day trading volume of 4.23 million shares is below the 3-month average of 4.99 million, indicating normal recent market interest.

Valuation Metrics

Elanco Animal Health Incorporated trades at a P/E ratio of -51.7, slightly below the S&P 500 average, with a price-to-sales ratio of 2.55 and a price-to-book ratio of 1.83 suggesting the stock is closer to book value. The P/FCF stands at 42.26, also above market averages.

Dividend & Fair Value

Elanco Animal Health Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.11. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Elanco Animal Health Incorporated generated EPS of -$0.47 over the past year. Five-year average earnings growth is 18.11%. Wall Street analysts project EPS growth of 11.86% annually over the next five years. The latest quarter delivered EPS of $0.19. The next quarter is forecast at $0.34. Next year's EPS is expected at -$1.20. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 6 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $17.00. The high target offers 24.43% upside. The low target suggests -29.49% downside. The mean target is $24.06. This offers -0.21% upside. Elanco Animal Health Incorporated earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 05, 2025, missed forecasts by 46.15%. The prior quarter beat by 30.0%. Over the last six quarters, Apple has recorded several small beats. These include 25.0% in August 08, 2024.

Shareholding & Insider Activity

Elanco Animal Health Incorporated has 496.81 million shares outstanding. The public float is 492.94 million shares, elevated short interest at 6.76% of float. This equals 24.29 million shares. The short ratio is 4.12 days. Institutional investors hold 111.03% of the float. Insiders own 1.03%. BAYER AKTIENGESELLSCHAFT holds 18.45 million shares, HOOVER R DAVID has 210.00 thousand shares and Simmons Jeffrey N has 167.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Elanco Animal Health generated $4.42B in revenue, or $8.97 per share. Gross margin was 56.28%, operating margin 7.38%, and net profit margin -27.87%. Returns are negative, with ROA at -8.57% and ROE at -19.78%.
On valuation metrics, Elanco Animal Health trades at a P/E of -51.70, P/S of 2.55 and P/B of 1.83. The current ratio is 2.17 and quick ratio is 1.08. Operationally, the company’s inventory turnover is 1.45 and cash conversion cycle is 270.66 days. Debt-to-equity is 0.61, supported by a cash flow-to-debt ratio of 0.14.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Elanco Animal Health posted revenue of $4.42B, down slightly from $4.42B in the prior quarter. Gross profit was $2.49B (margin 56.28%). Operating income was $326.00M (margin 7.4%). Net income was- $1.23B (EPS - $2.50).
The company ended the quarter with $352.00M in cash and short-term investments, a total debt of $5.77B, and net debt of $5.42B. Total assets were $14.36B, with equity of $6.22B. Financials further reflected stability, with operating cash flow of $271.00M, free cash flow of $117.00M, and capital expenditures of - $154.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Elanco Animal Health Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.36%, with price expected at $23.54 by April 28, 2026, within a range of $22.51 to $24.49 3-Month Outlook: Projected rise of 84.28%, reaching $44.43 by July 13, 2026, with a range of $44.09 to $44.84. 1-Year Outlook: Projected gain of 17.71%, with price at $28.38 by April 14, 2027, within a range of $27.10 to $29.64.

Key Takeaways

Elanco Animal Health Incorporated (NYSE:ELAN) shares are flat 6.76% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Elanco Animal Health Incorporated trading at a premium to the broader market with a P/E of -51.7. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $21.10, suggesting -12.48% downside. Our AI forecast model points to short-term weakness (-2.36% over two weeks), a medium-term rise (84.28% over three months), and a longer-term gain (17.71% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Elanco Animal Health Incorporated (ELAN) stock price?

Elanco Animal Health Incorporated (NYSE: ELAN) stock price is $23.23 in the last trading session. During the trading session, ELAN stock reached the peak price of $24.43 while $23.03 was the lowest point it dropped to. The percentage change in ELAN stock occurred in the recent session was -3.65% while the dollar amount for the price change in ELAN stock was - $0.88.

ELAN's industry and sector of operation?

The NYSE listed ELAN is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Elanco Animal Health Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ELAN?

Mr. Larbi Van Lier
Senior Vice President of Asia
Ms. Marcela A. Kirberger
Executive Vice President, Gen. Counsel & Corporation Sec.
Mr. Jeffrey N. Simmons
Pres, Chief Executive Officer & Director
Mr. David Alan Urbanek
Executive Vice President of Manufacturing & Quality
Katy Grissom
Head of Investor Relations
Mr. James M. Meer
Senior Vice President & Chief Accounting Officer
Mr. Shawn McKee
Senior Vice President of U.S. Companion Animal
Mr. Ramiro Martin Cabral
Executive Vice President & Pres of Elanco International
Mr. David S. Kinard
Executive Vice President of HR, Communications & Admin.
Dr. Ellen de Brabander Ph.D.
Executive Vice President of Innovation, Regulatory & Bus. Devel.
Mr. Rajeev Modi
Executive Vice President of U.S. Pet Health & Global Digital Transformation
Mr. Chris Keeley
Senior Vice President & Chief Information Officer
Mr. Todd S. Young
Executive Vice President & Chief Financial Officer
Mr. Jacques Zimmowitch
Senior Vice President of Global Quality
Dr. Ramiro Martin Cabral
Executive Vice President & Pres of Elanco International

How ELAN did perform over past 52-week?

ELAN's closing price is 200.62% higher than its 52-week low of $8.02 where as its distance from 52-week high of $27.72 is -13.02%.

How many employees does ELAN have?

Number of ELAN employees currently stands at 9,000.

Link for ELAN official website?

Official Website of ELAN is: https://www.elanco.com

How do I contact ELAN?

ELAN could be contacted at phone 877 352 6261 and can also be accessed through its website. ELAN operates from 2500 Innovation Way, Greenfield, IN 46140, United States.

How many shares of ELAN are traded daily?

ELAN stock volume for the day was 2.76M shares. The average number of ELAN shares traded daily for last 3 months was 5M.

What is the market cap of ELAN currently?

The market value of ELAN currently stands at $11.55B with its latest stock price at $23.23 and 497.17M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	9000
Beta	1.89
Sales or Revenue	$4.42B
5Y Sales Change%	-0.082%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

ELAN Company Profile and Key Details

Elanco Animal Health

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Valuation Metrics

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights